Objective: To investigate the performance of the simultaneous interocular brightness sense test in patients with ocular hypertension and primary open angle glaucoma (POAG).
Design: Brightness matches were obtained for an age-matched control sample and for patients with ocular hypertension and POAG. In addition, for the patients with POAG, visual field defects were quantified and a risk factor count was established for those with ocular hypertension.
Patients: Nineteen patients with ocular hypertension, 20 patients with POAG, and 61 age-matched controls participated in the study.
Results: Seven patients with ocular hypertension exhibited brightness perception asymmetry outside normal limits for age-matched controls. Of these, six were at high risk of having glaucoma develop and only one of the remaining 12 was found to be at similar risk. All 20 patients with established POAG had results outside the normal limits for a test sensitivity of 100%. Three control observers had abnormal results, giving a test specificity of 95%.
Conclusion: The simultaneous interocular brightness sense test is quick and simple to perform and is suitable for a wide age range of patients. It warrants further assessment as a means of screening for ocular hypertension and glaucoma.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1001/archopht.1994.01090210082020 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Phase 3, Randomized, Comparison Study of Intracameral Bimatoprost Implant 10 µg and Selective Laser Trabeculoplasty.
Am J Ophthalmol
January 2025
Piedmont Eye Center, Lynchburg, Virginia.
Purpose: To evaluate the intraocular pressure (IOP)-lowering effect and safety of up to two bimatoprost implant administrations versus selective laser trabeculoplasty (SLT).
Design: Phase 3 (Stage 2), randomized, 24-month, multicenter, patient- and efficacy evaluator-masked, paired-eye clinical trial (NCT02507687).
Participants: Patients (n=183) with open-angle glaucoma or ocular hypertension inadequately managed with topical IOP-lowering medication for reasons other than efficacy.
Stem Cell-Based Therapies for Glaucoma Treatment: A Review Bridging the Gap in Veterinary Patients.
Int J Mol Sci
December 2024
Centro de Estudos de Ciência Animal (CECA), Instituto de Ciências, Tecnologias e Agroambiente (ICETA) da Universidade do Porto (UP), Praça Gomes Teixeira, Apartado 55142, 4051-401 Porto, Portugal.
Retinal diseases are characterized by progressive damage to retinal cells, leading to irreversible vision loss. Among these, glaucoma stands out as a multifactorial neurodegenerative disease involving elevated intraocular pressure, retinal ganglion cell apoptosis, and optic nerve damage, ultimately resulting in blindness in both humans and dogs. Stem cell-based therapies have emerged as a promising therapeutic option for such conditions due to their regenerative and neuroprotective potential.
View Article and Find Full Text PDFXen 63 versus Preserflo MicroShunt implant in patients with primary open-angle glaucoma.
Sci Rep
January 2025
Department of Ophthalmology and ORL, Faculty of Medicine, Clinico San Carlos Hospital, Complutense University, Clinico San Carlos Hospital Health Research Institute (IdISSC), Calle del Prof Martín Lagos, s/n,, Madrid, 28040, Spain.
This study compared the efficacy safety profiles of the Xen 63 and Preserflo MicroShunt devices, both standalone, in patients with primary open-angle glaucoma (POAG). It is a retrospective and single-center study conducted on consecutive on patients with medically uncontrolled POAG who underwent either a standalone Xen 63 or a standalone Preserflo and had a 12-month follow-up visit. The primary outcome was the mean IOP at month-12.
View Article and Find Full Text PDFTailoring glaucoma education using large language models: Addressing health disparities in patient comprehension.
Medicine (Baltimore)
January 2025
School of Medicine, University of California, Irvine, Irvine, CA.
This study evaluates the efficacy of GPT-4, a Large Language Model, in simplifying medical literature for enhancing patient comprehension in glaucoma care. GPT-4 was used to transform published abstracts from 3 glaucoma journals (n = 62) and patient education materials (Patient Educational Model [PEMs], n = 9) to a 5th-grade reading level. GPT-4 was also prompted to generate de novo educational outputs at 6 different education levels (5th Grade, 8th Grade, High School, Associate's, Bachelor's and Doctorate).
View Article and Find Full Text PDFFABP5 regulates ROS-NLRP3 inflammasome in glutamate-induced retinal excitotoxic glaucomatous model.
FASEB J
January 2025
Department of Eye Center, Xiangya Hospital, Central South University, Changsha, China.
Fatty acid binding proteins (FABPs) are a class of small molecular mass intracellular lipid chaperone proteins that bind to hydrophobic ligands, such as long-chain fatty acids. FABP5 expression was significantly upregulated in the N-methyl-d-aspartic acid (NMDA) model, the microbead-induced chronic glaucoma model, and the DBA/2J mice. Previous studies have demonstrated that FABP5 can mediate mitochondrial dysfunction and oxidative stress in ischemic neurons, but the role of FABP5 in oxidative stress and cell death in retina NMDA injury models is unclear.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!